We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

357 hedge funds and large institutions have $8.94B invested in Jazz Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 126 increasing their positions, 120 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 36

25% more funds holding in top 10

Funds holding in top 10: 1215 (+3)

10% more funds holding

Funds holding: 325357 (+32)

5% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 120

4% more capital invested

Capital invested by funds: $8.58B → $8.94B (+$355M)

27% less call options, than puts

Call options by funds: $86.4M | Put options by funds: $119M

Holders
357
Holders Change
+32
Holders Change %
+9.85%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.4%
New
76
Increased
126
Reduced
120
Closed
36
Calls
$86.4M
Puts
$119M
Net Calls
-$32.4M
Net Calls Change
+$92.4M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
126
VOYA Investment Management
Georgia
$4.66M -$246K -1,484 -5%
EVM
127
Eaton Vance Management
Massachusetts
$4.62M -$1.93M -11,623 -29%
BlackRock
128
BlackRock
New York
$4.61M +$4.28M +25,769 +1,096%
MIG
129
Mariner Investment Group
New York
$4.6M +$498K +3,000 +12%
Comerica Bank
130
Comerica Bank
Texas
$4.58M +$2.17M +13,073 +88%
Citigroup
131
Citigroup
New York
$4.26M -$18.8M -113,484 -81%
RSCM
132
Rock Springs Capital Management
Maryland
$4.09M +$1.12M +6,750 +37%
AIA
133
Affinity Investment Advisors
California
$4.03M
3NC
134
300 North Capital
California
$4.03M +$751K +4,524 +23%
Victory Capital Management
135
Victory Capital Management
Texas
$3.96M +$4.01M +24,155 New
TCM
136
Timpani Capital Management
Wisconsin
$3.91M -$779K -4,696 -16%
WGCA
137
Wolf Group Capital Advisors
Virginia
$3.84M -$176K -1,060 -4%
ACP
138
Aviance Capital Partners
Florida
$3.79M -$198K -1,195 -5%
DCM
139
Dupont Capital Management
Delaware
$3.7M +$1.83M +11,051 +96%
Stifel Financial
140
Stifel Financial
Missouri
$3.65M +$554K +3,337 +18%
M&T Bank
141
M&T Bank
New York
$3.63M +$335K +2,020 +10%
GCP
142
GSA Capital Partners
United Kingdom
$3.59M +$2.37M +14,277 +186%
AA
143
AlphaMark Advisors
Kentucky
$3.55M -$91.5K -551 -2%
Aviva
144
Aviva
United Kingdom
$3.45M +$6.64K +40 +0.2%
CM
145
Castleark Management
Illinois
$3.42M -$3.27M -19,681 -49%
SG Americas Securities
146
SG Americas Securities
New York
$3.39M +$2.53M +15,261 +281%
ABI
147
Adamant Biomedical Investments
Switzerland
$3.27M
SGH
148
Sivik Global Healthcare
Connecticut
$3.24M -$863K -5,200 -21%
GC
149
Guggenheim Capital
Illinois
$3.24M +$898K +5,409 +38%
TAM
150
Tealwood Asset Management
Minnesota
$3.11M -$43.5K -262 -1%

JAZZ Hedge Fund Activity: Q4 2014 in Review

357 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2014, worth a combined $8.94B — up 4.1% from $8.58B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 36 closed out — a net gain of 40 holders — while 126 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $71.4M. The largest seller was Wells Fargo, cutting an estimated $119M.

  • 357 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2014, up from 325 in Q3 2014.
  • Funds reported $8.94B of Jazz Pharmaceuticals stock for Q4 2014, up 4.1% quarter-over-quarter.
  • 76 funds opened new Jazz Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +40 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2014 was American Century Companies, an estimated $71.4M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2014 was Wells Fargo, an estimated $119M sold.

Based on aggregated 13F filings for Q4 2014.